Search International and National Patent Collections

1. (WO2018221820) METHOD FOR ASSESSING IMMUNITY AND PROVIDING INFORMATION ON WHETHER OR NOT THE ONSET OF CANCER HAS BEGUN BY UTILIZING DIFFERENCE IN IMMUNE CELL DISTRIBUTION BETWEEN PERIPHERAL BLOOD OF COLORECTAL CANCER PATIENT AND NORMAL PERSON, AND DIAGNOSTIC KIT USING SAME

Pub. No.:    WO/2018/221820    International Application No.:    PCT/KR2018/000505
Publication Date: Fri Dec 07 00:59:59 CET 2018 International Filing Date: Fri Jan 12 00:59:59 CET 2018
IPC: G01N 33/574
G01N 33/58
G01N 33/569
G01N 15/14
Applicants: LEE, Jong Kyun
이종균
Inventors: LEE, Jong Kyun
이종균
CHOI, Joung Bum
최중범
Title: METHOD FOR ASSESSING IMMUNITY AND PROVIDING INFORMATION ON WHETHER OR NOT THE ONSET OF CANCER HAS BEGUN BY UTILIZING DIFFERENCE IN IMMUNE CELL DISTRIBUTION BETWEEN PERIPHERAL BLOOD OF COLORECTAL CANCER PATIENT AND NORMAL PERSON, AND DIAGNOSTIC KIT USING SAME
Abstract:
Provided according to the present invention is a method for assessing immunity of peripheral blood and providing information on whether or not the onset of colorectal cancer has begun by utilizing a difference in immune cell distribution between peripheral blood of colorectal cancer patients and normal persons, the method comprising the steps of: (A) analyzing peripheral blood immune cells for cell size and wrinkle degree to classify the cells into lymphocytes, monocytes, and granulocytes; (B) staining a labeling marker of the three kinds of immune cells with at least one antibody combination to analyze the distribution of immune cells in peripheral bloods of cancer patients and normal persons; (C) discriminating sets in which meaningful result values of the labeling marker are different between the two groups, cancer patients and normal persons, with statistical significance, so as to discriminate whether or not the onset of cancer has begun among cancer patients and normal persons; and (D) measuring immunity per unit of blood by means of the labeling marker to diagnose whether or not the onset of colorectal cancer has begun, without counting natural killer cells with a flow cytometer or a cell counter.